Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.38 |
| ▸ | CDC25B | P30305 | 7/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | RIPK1 | Q13546 | 4/20 | 0.36 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.35 |
| ▸ | PTPN2 | P17706 | 3/20 | 0.35 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.35 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.35 |
| ▸ | PDE2A | O00408 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23960116 | 0.92 | HSPA5 (0.35) | PTPN1CDC25BBCHERIPK1HSPA5 | |
| SCHEMBL27086454 | 0.86 | PDE2A (0.37) | PTPN1CDC25BBCHEHSPA5PTPN2 | |
| SCHEMBL12243141 | 0.86 | PDE2A (0.37) | PTPN1CDC25BBCHEHSPA5PTPN2 | |
| SCHEMBL12393373 | 0.86 | PDE2A (0.37) | PTPN1CDC25BBCHEHSPA5PTPN2 | |
| SCHEMBL31063739 | 0.86 | PDE2A (0.37) | PTPN1CDC25BBCHEHSPA5PTPN2 | |
| SCHEMBL12393257 | 0.85 | PDE2A (0.37) | PTPN1CDC25BBCHEHSPA5PTPN2 | |
| SCHEMBL18636443 | 0.85 | PDE2A (0.37) | PTPN1CDC25BBCHEHSPA5PTPN2 | |
| SCHEMBL14039002 | 0.84 | PDE2A (0.37) | PTPN1CDC25BHSPA5PTPN2PTPN6 | |
| SCHEMBL25826686 | 0.84 | PDE2A (0.36) | PTPN1CDC25BBCHEHSPA5PTPN2 | |
| SCHEMBL12393377 | 0.84 | PTPN1 (0.36) | PTPN1CDC25BBCHEHSPA5PTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | VIGONVITA LIFE SCIENCES CO., LTD. (CN) | 2023-07-13 | — | — | US | disclosed |
| WO-2021213288-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | 中国科学院上海药物研究所 (CN) | 2021-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219993-A1 | ANTIVIRAL APPLICATION OF NUCLEOSIDE ANALOG OR COMBINATION FORMULATION CONTAINING NUCLEOSIDE ANALOG | PNP, TYMP, PIGS | PTPN1 2048/4885CDC25B 880/4885BCHE 1889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.